Skip to main content

Advertisement

Table 1 Demographic data and biomarker CSF levels for the diagnostic groups a

From: SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer’s disease

German cohort Control Prodromal Alzheimer’s disesase Alzheimer’s disease
Number (Men/Women) 9 (2/7) 7 (4/3) 9 (3/6)
Age (years) 70 (68-74) 72 (69-73) 68 (68-79)
MMSE 27 (25-29) 28 (27-28) 22 (21-23) P = 0.02b, P = 0.001c
Aβ1-42 (ng/L) 1065 (797-1201) 541 (521-753) P = 0.005b 524 (424-695) P = 0.0005b
T-tau (ng/L) 165 (135-208) 403 (353-513) P = 0.0002b 779 (683-864) P = 0.00004b, P = 0.002c
P-tau181 (ng/L) 45 (38-50) 81 (76-95) P = 0.0002b 130 (108-161) P = 0.00004b, P = 0.005c
Swedish cohort I Control Prodromal Alzheimer’s disesase Alzheimer’s disease
Number (Men/Women) 6 (1/5)   10 (3/7)
Age (years) 54 (48-63)   77 (73-82) P = 0.001b
MMSE 27 (27-28)   24 (22-25) P = 0.0003b
Aβ1-42 (ng/L) 915 (860-1040)   470 (355-560) P = 0.0003b
T-tau (ng/L) 290 (230-300)   690 (590-1100) P = 0.0002b
P-tau181 (ng/L) 56 (40-60)   92 (84-132) P = 0.0003b
Swedish cohort II Control Prodromal Alzheimer’s disesase Alzheimer’s disease
Number (Men/Women) 17 (9/8)   17 (5/12)
Age (years) 66 (64-68)   68 (66-70)
MMSE 30 (29-30)   25 (24-27) P < 0.0001b
Aβ1-42 (ng/L) 640 (530-870)   320 (210-440) P = 0.0001b
T-tau (ng/L) 250 (180-320)   560 (360-1020) P = 0.0006b
P-tau181 (ng/L) 46 (34-58)   93 (54-127) P = 0.001b
  1. Abbreviations: Aβ1-42 (amyloidβ 1-42), CSF (cerebrospinal fluid), MMSE (mini-mental state examination), T-tau (total tau), P-tau181 (tau phosphorylated at threonine 181).
  2. aData are given as median (interquartile range) unless otherwise indicated. Statistical differences were determined using nonparametric tests.
  3. bCompared with controls.
  4. cCompared with prodromal Alzheimer’s disease.